Corcept Therapeutics (CORT) said late Thursday that its phase 4 Catalyst trial of Korlym showed a reduction in hemoglobin A1c in patients with hypercortisolism, or Cushing's syndrome, and difficult-to-control type 2 diabetes, meeting the study's primary endpoint.

Korlym-treated patients demonstrated a 1.47% reduction in hemoglobin A1c, compared with a 0.15% decrease in the placebo group, the company said.

The trial included a screening phase with 1,057 patients with type 2 diabetes. About 24% of these patients had hypercortisolism and were eligible to enter the trial's treatment phase, in which 136 patients were randomized to receive either Korlym or placebo for 24 weeks, the company said.

The study's safety profile was consistent with Korlym's label, and no new side effects or adverse events were observed, the company added.

Corcept said complete results will be presented at a medical conference in 2025.

Shares of Corcept were up 0.8% in recent after-hours activity.

Price: 56.80, Change: +0.47, Percent Change: +0.84